Jefferies Group Raises Indivior (INDV) Price Target to GBX 610

Indivior (LON:INDV) had its price target hoisted by equities research analysts at Jefferies Group from GBX 500 ($7.02) to GBX 610 ($8.56) in a note issued to investors on Monday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Jefferies Group’s price objective suggests a potential upside of 55.22% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. Numis Securities reissued a “buy” rating and issued a GBX 600 ($8.42) price objective on shares of Indivior in a research report on Friday, March 23rd. Royal Bank of Canada upped their price objective on shares of Indivior from GBX 500 ($7.02) to GBX 540 ($7.58) and gave the company an “outperform” rating in a research report on Friday, January 26th. Finally, Morgan Stanley upped their price objective on shares of Indivior from GBX 450 ($6.32) to GBX 455 ($6.39) and gave the company an “equal weight” rating in a research report on Tuesday, April 3rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Indivior has a consensus rating of “Buy” and an average price target of GBX 515.83 ($7.24).

How to Become a New Pot Stock Millionaire

Shares of Indivior stock opened at GBX 393 ($5.52) on Monday. Indivior has a twelve month low of GBX 246.50 ($3.46) and a twelve month high of GBX 436.60 ($6.13).

In other Indivior news, insider Mark Crossley sold 130,501 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of GBX 379 ($5.32), for a total value of £494,598.79 ($694,271.18). Also, insider Shaun Thaxter sold 551,896 shares of the company’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of GBX 404 ($5.67), for a total transaction of £2,229,659.84 ($3,129,786.41).

COPYRIGHT VIOLATION WARNING: This news story was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3342349/jefferies-group-raises-indivior-indv-price-target-to-gbx-610.html.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The company's product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia.

Analyst Recommendations for Indivior (LON:INDV)

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Critical Review: Codexis  & FutureFuel
Critical Review: Codexis & FutureFuel
Reviewing iRobot  and SodaStream
Reviewing iRobot and SodaStream
Bitauto Hldg Ltd  Given Consensus Recommendation of “Hold” by Brokerages
Bitauto Hldg Ltd Given Consensus Recommendation of “Hold” by Brokerages
Eldorado Gold Corp  Receives Consensus Recommendation of “Hold” from Brokerages
Eldorado Gold Corp Receives Consensus Recommendation of “Hold” from Brokerages
Analysts Anticipate Sogou  to Announce $0.05 EPS
Analysts Anticipate Sogou to Announce $0.05 EPS
AK Steel  versus Its Peers Head-To-Head Contrast
AK Steel versus Its Peers Head-To-Head Contrast


© 2006-2018 Ticker Report. Google+.